Figures & data
Figure 1. Characterization of ADSCs. (a) Flow cytometry analysis for the detection of ADSC surface markers. (b) Morphology of ADSCs. (c) Osteogenic ADSCs. (d) Adipogenic ADSCs.
Figure 2. EGFL6 knockdown attenuates the osteogenic differentiation of ADSCs. (a) mRNA expression of EGFL6 in ADSCs. (b) Protein expression of EGFL6 in ADSCs. (c) ARS staining of ADSCs. (d) ALP activity of ADSCs. (e) mRNA expression of RUNX2 in ADSCs. (f) mRNA expression of OPN in ADSCs. (g) mRNA expression of OCN in ADSCs. (h) Protein expression of RUNX2, OPN, and OCN. **P < 0.01, *** P < 0.001 versus si-NC.
Figure 3. Recombinant EGFL6 promotes osteogenic differentiation of ADSCs. (a) ARS stain of ADSCs. (b) ALP activity of ADSCs. (c) mRNA expression of RUNX2 in ADSCs. (d) mRNA expression of OPN in ADSCs. (e) mRNA expression of OCN in ADSCs. (f) Protein expression of RUNX2, OPN, OCN. ##P < 0.01, **P < 0.01, ***P < 0.001 versus si-NC.
Figure 4. The expression of BMP2 and SMAD4 is positively correlated with EGFL6. (a) Protein expression of BMP2 as well as SMAD4. ##P < 0.01, ***P < 0.001 versus si-NC.
Figure 5. Recombinant EGFL6 enhances osteogenic differentiation through the BMP2/SMAD4 signaling pathway. (a) mRNA expression of BMP2. (b) Protein expression of BMP2 and SMAD4. (c) ARS staining of ADSCs. (d) ALP activity of ADSCs. (e) mRNA expression of RUNX2 in ADSCs. (f) mRNA expression of OPN in ADSCs. (g) mRNA expression of OCN in ADSCs. (h) Protein expression of RUNX2, OPN, and OCN. ##P < 0.01, **P < 0.01, ***P < 0.001 versus si-NC.
